Epizyme is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them. 

Based on clinical proof of concept in treating multiple forms of cancer, Epizyme's lead product candidate, tazemetostat, is being developed for hematologic malignancies and genetically defined solid tumors. The Company is also advancing novel compounds directed against a broad range of disease targets.

Type
Public
HQ
Cambridge, US
Founded
2007
Size (employees)
112 (est)
Epizyme was founded in 2007 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Epizyme

Robert A. Copeland

Robert A. Copeland

Executive Vice President and Chief Scientific Officer

Epizyme Office Locations

Epizyme has an office in Cambridge
Cambridge, US (HQ)
400 Technology Square
Show all (1)
Report incorrect company information

Epizyme Financials and Metrics

Epizyme Financials

Epizyme's revenue was reported to be $8.01 m in FY, 2016 which is a 212.8% increase from the previous period.
USD

Net income (Q1, 2018)

(34.1 m)

EBIT (Q1, 2018)

(35 m)

Market capitalization (14-Jun-2018)

1.1 b

Closing share price (14-Jun-2018)

15.9

Cash (31-Mar-2018)

130.3 m
Epizyme's current market capitalization is $1.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

68.5 m41.4 m2.6 m8 m

Revenue growth, %

(40%)(94%)213%

General and administrative expense

28.4 m37.2 m

R&D expense

91.5 m109.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

General and administrative expense

3.6 m5 m5.3 m5.7 m5.2 m6 m6.7 m5.8 m7.4 m7.5 m8.3 m11.2 m9.3 m9.4 m

R&D expense

14.6 m15.3 m17.5 m22.2 m57.1 m20.6 m16.8 m17.7 m21.5 m23.9 m24.7 m27.3 m28.7 m25.6 m

Operating expense total

18.2 m20.3 m22.8 m27.9 m62.3 m26.5 m23.5 m23.6 m28.9 m31.4 m33 m38.5 m38.1 m35 m

EBIT

(9.7 m)(6.9 m)(13.3 m)(19.7 m)(61.4 m)(25.8 m)(23.1 m)(23.1 m)(28.4 m)(24.8 m)(33 m)(28.5 m)(38.1 m)(35 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

123.6 m190.1 m208.3 m77.9 m226.7 m

Accounts Receivable

33.7 m2.1 m262 k23 k382 k

Inventories

2.4 m2.8 m4.5 m6.5 m

Current Assets

159.7 m195 m213.1 m248.7 m285.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

139.6 m237.1 m229.9 m211.7 m244.5 m236.7 m229.9 m312.7 m89.5 m66 m64.4 m88.5 m219.8 m130.3 m

Accounts Receivable

2.2 m8.2 m2.2 m2.1 m365 k723 k177 k176 k60 k6.2 m8 k25 k25 k24 k

Current Assets

143.9 m247.3 m234.7 m217.1 m247.4 m239.4 m232.6 m318.3 m296.6 m275 m220 m201.7 m317.3 m256.9 m

PP&E

2 m2.6 m2.6 m2.7 m5.2 m4.9 m4.5 m3.8 m3.6 m3.3 m3.3 m3 m2.6 m2.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(3.5 m)(55 m)(132.4 m)(110.2 m)(134.3 m)

Depreciation and Amortization

703 k742 k1.4 m1.6 m1.6 m

Inventories

(1.5 m)(419 k)(1.6 m)(1.5 m)

Accounts Payable

1.6 m3.6 m(3.6 m)341 k2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(19.4 m)(6.9 m)(20.3 m)(40 m)(61.3 m)(25.8 m)(23.1 m)(22.9 m)(28 m)(24.3 m)(32.5 m)(34.1 m)

Depreciation and Amortization

534 k169 k362 k548 k260 k389 k361 k

Accounts Payable

364 k(1.3 m)(142 k)1.1 m(3.2 m)3 m3 m(2.4 m)3.7 m3.4 m7.3 m226 k

Cash From Operating Activities

(38 m)11.9 m4.7 m(14.4 m)(22.7 m)(25.4 m)(30.3 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Epizyme Online and Social Media Presence

Embed Graph
Report incorrect company information

Epizyme News and Updates

Report incorrect company information